Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cough | 13 | 2023 | 183 | 3.260 |
Why?
|
| Antitussive Agents | 2 | 2023 | 11 | 1.590 |
Why?
|
| Trachea | 10 | 2005 | 83 | 1.350 |
Why?
|
| Muscle, Smooth | 9 | 2008 | 135 | 1.300 |
Why?
|
| Interleukin-4 | 4 | 2008 | 147 | 0.870 |
Why?
|
| Calcium | 7 | 2008 | 584 | 0.800 |
Why?
|
| Nalbuphine | 1 | 2023 | 3 | 0.800 |
Why?
|
| Calcium Signaling | 4 | 2006 | 164 | 0.780 |
Why?
|
| Chronic Disease | 10 | 2023 | 742 | 0.690 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 162 | 0.680 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2020 | 7 | 0.630 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 41 | 0.610 |
Why?
|
| Cyclic AMP | 6 | 2006 | 144 | 0.570 |
Why?
|
| Lung Diseases | 1 | 2020 | 183 | 0.560 |
Why?
|
| Gastroesophageal Reflux | 6 | 2010 | 93 | 0.510 |
Why?
|
| Cattle | 11 | 2005 | 320 | 0.410 |
Why?
|
| Respiratory System | 2 | 2005 | 46 | 0.410 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 707 | 0.400 |
Why?
|
| Carbachol | 6 | 2005 | 17 | 0.360 |
Why?
|
| Adenylyl Cyclase Inhibitors | 3 | 2000 | 8 | 0.310 |
Why?
|
| Bronchi | 3 | 2008 | 85 | 0.310 |
Why?
|
| Receptors, Muscarinic | 3 | 2000 | 18 | 0.270 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2008 | 31 | 0.270 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2008 | 16 | 0.270 |
Why?
|
| Caffeine | 4 | 2002 | 46 | 0.270 |
Why?
|
| Humans | 25 | 2023 | 65498 | 0.260 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 2006 | 4 | 0.240 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2006 | 10 | 0.240 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2006 | 62 | 0.230 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2005 | 45 | 0.230 |
Why?
|
| Bronchodilator Agents | 2 | 2003 | 122 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 367 | 0.210 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2005 | 145 | 0.200 |
Why?
|
| Triage | 1 | 2005 | 137 | 0.200 |
Why?
|
| Nasal Decongestants | 1 | 2003 | 2 | 0.200 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 11 | 0.200 |
Why?
|
| Patient Admission | 1 | 2005 | 199 | 0.200 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 49 | 0.190 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 1565 | 0.190 |
Why?
|
| Pyrimidines | 1 | 2023 | 144 | 0.190 |
Why?
|
| Muscarinic Antagonists | 2 | 2000 | 34 | 0.190 |
Why?
|
| Chromones | 1 | 2002 | 18 | 0.190 |
Why?
|
| Cytosol | 2 | 2001 | 182 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2023 | 133 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2020 | 233 | 0.180 |
Why?
|
| Asthma | 4 | 2012 | 485 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2010 | 990 | 0.180 |
Why?
|
| Androstadienes | 1 | 2002 | 43 | 0.180 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2000 | 34 | 0.180 |
Why?
|
| Pneumonia | 1 | 2005 | 295 | 0.180 |
Why?
|
| Nose Diseases | 1 | 2002 | 7 | 0.180 |
Why?
|
| Paranasal Sinuses | 1 | 2002 | 7 | 0.180 |
Why?
|
| Morpholines | 1 | 2002 | 91 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2005 | 435 | 0.170 |
Why?
|
| Cell Movement | 1 | 2003 | 482 | 0.170 |
Why?
|
| Indoles | 1 | 2001 | 112 | 0.160 |
Why?
|
| Albuterol | 1 | 2000 | 24 | 0.160 |
Why?
|
| Fura-2 | 4 | 2005 | 8 | 0.160 |
Why?
|
| Cells, Cultured | 4 | 2008 | 2188 | 0.160 |
Why?
|
| Intracellular Membranes | 2 | 2001 | 47 | 0.160 |
Why?
|
| Receptors, Purinergic P2X3 | 1 | 2020 | 5 | 0.160 |
Why?
|
| United Kingdom | 1 | 2020 | 85 | 0.160 |
Why?
|
| Sarcoplasmic Reticulum | 3 | 2005 | 14 | 0.160 |
Why?
|
| Clinical Medicine | 1 | 2019 | 16 | 0.150 |
Why?
|
| Negotiating | 1 | 2019 | 16 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2020 | 180 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2019 | 85 | 0.140 |
Why?
|
| Fluorescent Dyes | 4 | 2005 | 202 | 0.140 |
Why?
|
| Isoproterenol | 2 | 1996 | 37 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 220 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 529 | 0.140 |
Why?
|
| Double-Blind Method | 1 | 2020 | 744 | 0.140 |
Why?
|
| Leadership | 1 | 2019 | 212 | 0.130 |
Why?
|
| Animals | 11 | 2005 | 21394 | 0.120 |
Why?
|
| Common Cold | 2 | 2010 | 9 | 0.120 |
Why?
|
| Cholinergic Agents | 1 | 1996 | 8 | 0.120 |
Why?
|
| Bronchitis | 2 | 2010 | 30 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 2633 | 0.100 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 491 | 0.090 |
Why?
|
| Adult | 4 | 2020 | 17467 | 0.090 |
Why?
|
| Meditation | 1 | 2012 | 54 | 0.090 |
Why?
|
| Radiography | 2 | 2005 | 558 | 0.090 |
Why?
|
| Muscarinic Agonists | 2 | 2005 | 8 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 741 | 0.080 |
Why?
|
| Cell Separation | 2 | 2005 | 147 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 1172 | 0.080 |
Why?
|
| Clinical Protocols | 2 | 2001 | 138 | 0.080 |
Why?
|
| Laryngitis | 1 | 2008 | 2 | 0.070 |
Why?
|
| Osmolar Concentration | 2 | 2001 | 91 | 0.070 |
Why?
|
| Global Health | 1 | 2010 | 181 | 0.070 |
Why?
|
| Candida | 1 | 2008 | 37 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 2008 | 49 | 0.070 |
Why?
|
| Candidiasis | 1 | 2008 | 49 | 0.070 |
Why?
|
| Histamine | 1 | 2008 | 21 | 0.070 |
Why?
|
| Interleukin-13 | 1 | 2008 | 37 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 133 | 0.070 |
Why?
|
| Dust | 1 | 2008 | 42 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 91 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2006 | 3156 | 0.070 |
Why?
|
| Kinetics | 2 | 2000 | 757 | 0.070 |
Why?
|
| Acute Disease | 2 | 2000 | 663 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2008 | 140 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2012 | 475 | 0.070 |
Why?
|
| Dyspnea | 1 | 2008 | 120 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2005 | 2111 | 0.060 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2006 | 5 | 0.060 |
Why?
|
| Biological Transport, Active | 1 | 2006 | 38 | 0.060 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2006 | 46 | 0.060 |
Why?
|
| Cyclic ADP-Ribose | 1 | 2005 | 1 | 0.060 |
Why?
|
| Ionomycin | 1 | 2005 | 16 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 93 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 1998 | 401 | 0.060 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2005 | 13 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 272 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2008 | 322 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 185 | 0.050 |
Why?
|
| Quality of Life | 1 | 2012 | 1263 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 95 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 178 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2003 | 9 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 611 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 27 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3774 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 142 | 0.050 |
Why?
|
| Antigens, Helminth | 1 | 2002 | 10 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2002 | 252 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2005 | 1021 | 0.040 |
Why?
|
| Age Distribution | 1 | 2002 | 262 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2003 | 190 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2001 | 33 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 43 | 0.040 |
Why?
|
| Middle Aged | 4 | 2012 | 18393 | 0.040 |
Why?
|
| Whooping Cough | 1 | 2000 | 10 | 0.040 |
Why?
|
| Rhinitis | 1 | 2000 | 15 | 0.040 |
Why?
|
| Salmeterol Xinafoate | 1 | 2000 | 7 | 0.040 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2000 | 12 | 0.040 |
Why?
|
| Sinusitis | 1 | 2000 | 21 | 0.040 |
Why?
|
| Propranolol | 1 | 2000 | 22 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 34 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2000 | 41 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 662 | 0.040 |
Why?
|
| Reflex | 1 | 2000 | 27 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2000 | 139 | 0.040 |
Why?
|
| Research | 1 | 2001 | 195 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 235 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 175 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 708 | 0.040 |
Why?
|
| Genistein | 1 | 1998 | 9 | 0.040 |
Why?
|
| Organizational Culture | 1 | 2019 | 117 | 0.030 |
Why?
|
| Steroids | 1 | 1998 | 56 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 308 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1998 | 61 | 0.030 |
Why?
|
| Nickel | 1 | 1998 | 67 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 372 | 0.030 |
Why?
|
| Prognosis | 1 | 2002 | 1789 | 0.030 |
Why?
|
| Male | 4 | 2012 | 31208 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 1115 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 168 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2002 | 2067 | 0.030 |
Why?
|
| Propylbenzilylcholine Mustard | 1 | 1996 | 1 | 0.030 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1996 | 2 | 0.030 |
Why?
|
| Phenoxybenzamine | 1 | 1996 | 3 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 58 | 0.030 |
Why?
|
| Adenylate Cyclase Toxin | 1 | 1995 | 3 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 1995 | 3 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 1995 | 9 | 0.030 |
Why?
|
| Pertussis Toxin | 1 | 1995 | 14 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 1995 | 24 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1995 | 15 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 1998 | 299 | 0.030 |
Why?
|
| Lung | 1 | 2000 | 969 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 42 | 0.030 |
Why?
|
| Ryanodine | 1 | 1995 | 10 | 0.030 |
Why?
|
| Photolysis | 1 | 1995 | 15 | 0.030 |
Why?
|
| Manganese | 1 | 1995 | 20 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 5650 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1995 | 94 | 0.030 |
Why?
|
| Female | 3 | 2012 | 34216 | 0.030 |
Why?
|
| Child | 1 | 2002 | 4623 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 806 | 0.020 |
Why?
|
| United States | 1 | 2005 | 8149 | 0.020 |
Why?
|
| Risk Factors | 1 | 2002 | 5462 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 195 | 0.020 |
Why?
|
| Hospitalization | 1 | 1998 | 1402 | 0.020 |
Why?
|
| Aged | 1 | 2005 | 15062 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2008 | 61 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2008 | 125 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 460 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2778 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 2495 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 42 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2001 | 27 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 46 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 5811 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2001 | 109 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 1659 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 324 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 213 | 0.010 |
Why?
|
| Esophagus | 1 | 2000 | 47 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2001 | 414 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 663 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 700 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 962 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 586 | 0.010 |
Why?
|